{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T10:12:29Z","timestamp":1766830349410,"version":"build-2065373602"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.eplepsyres.2018.08.001","type":"journal-article","created":{"date-parts":[[2018,8,6]],"date-time":"2018-08-06T05:27:45Z","timestamp":1533533265000},"page":"119-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Drug interactions with carbamazepine: An ever expanding list?"],"prefix":"10.1016","volume":"147","author":[{"given":"Emilio","family":"Perucca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2018.08.001_bib0005","unstructured":"Ahn, J.E., Bathena, S.P.R., Brundage, R.C., Conway, J.M., Leppik, I.E., Birnbaum, A.K., Iron supplements in nursing home patients associated with reduced carbamazepine absorption. Epilepsy Res (in this issue)."},{"key":"10.1016\/j.eplepsyres.2018.08.001_bib0010","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1046\/j.1528-1157.2003.62202.x","article-title":"Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data","volume":"44","author":"Battino","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.08.001_bib0015","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1365-2125.1991.tb05525.x","article-title":"Iron supplements: a common cause of drug interactions","volume":"31","author":"Campbell","year":"1991","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2018.08.001_bib0020","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1365-2125.1992.tb04089.x","article-title":"Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites","volume":"33","author":"Kudriakova","year":"1992","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2018.08.001_bib0025","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(03)00409-5","article-title":"Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs","volume":"2","author":"Patsalos","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.eplepsyres.2018.08.001_bib0030","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1474-4422(03)00483-6","article-title":"Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs","volume":"2","author":"Patsalos","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.eplepsyres.2018.08.001_bib0035","doi-asserted-by":"crossref","first-page":"576","DOI":"10.2165\/00003088-198005060-00006","article-title":"Effect of dose increments on serum carbamazepine concentration in epileptic patients","volume":"5","author":"Perucca","year":"1980","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.eplepsyres.2018.08.001_bib0040","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/jcph.439","article-title":"Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects","volume":"55","author":"Song","year":"2015","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2018.08.001_bib0045","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2165\/00003088-199631030-00004","article-title":"Clinically significant pharmacokinetic drug interactions with carbamazepine; an update","volume":"31","author":"Spina","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eplepsyres.2018.08.001_bib0050","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/00007691-198909000-00008","article-title":"Relationship of intraindividual dose to plasma concentration of carbamazepine: indication of dose-dependent induction of metabolism","volume":"11","author":"Tomson","year":"1989","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.eplepsyres.2018.08.001_bib0055","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1684\/epd.2014.0714","article-title":"Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs","volume":"16","author":"Zaccara","year":"2014","journal-title":"Epileptic. Disord."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121118303735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121118303735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:40:53Z","timestamp":1760276453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121118303735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":11,"alternative-id":["S0920121118303735"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2018.08.001","relation":{},"ISSN":["0920-1211"],"issn-type":[{"type":"print","value":"0920-1211"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug interactions with carbamazepine: An ever expanding list?","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2018.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2018.07.015","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}